Roivant Sciences Ltd Ordinary Shares ROIV
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
Immunovant to Report Financial Results for the Second Fiscal Quarter Ended September 30, 2026, and Provide Business Update on Monday, November 9, 2026
-
Roivant and Priovant Announce Positive Results in CLARITY-1 and CLARITY-2 Phase 3 Trials for Brepocitinib in Non-Infectious Uveitis (NIU)
-
Roivant to Report Financial Results for the Second Quarter Ended September 30, 2026, and Provide Business Update on Monday, November 9, 2026
-
Roivant Announces Topline Results from Proof-of-Concept Study of IMVT-1402 in Cutaneous Lupus Erythematosus
-
Roivant Announces Positive Results from PHocus Study of Mosliciguat in Patients with Pulmonary Hypertension Associated with Interstitial Lung Disease (PH-ILD) and Unveils Ongoing Phase 3 PHrontier Study
-
Roivant to Present Topline Results from the Phase 2 PHocus Study of Mosliciguat in Patients with Pulmonary Hypertension Associated with Interstitial Lung Disease (PH-ILD) at the ERS Congress 2026 on Tuesday, September 8, 2026, and Host Investor Call
-
Roivant Announces FDA Approval of LISRAYA™ (brepocitinib) for Adults with Dermatomyositis; Now Available in the U.S.
-
Priovant Announces FDA Approval of LISRAYA™ (brepocitinib) for Adults with Dermatomyositis; Now Available in the U.S.
Trading Information
- Previous Close Price
- $34.92
- Day Range
- $35.99–38.49
- 52-Week Range
- $17.54–42.50
- Bid/Ask
- $36.50 / $37.30
- Shares Outstanding
- 722.32M
- Market Cap
- $26.58B
- Volume/Avg
- 17M / 7M
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 3,439.57
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- 0.47%
Company Profile
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Large Core
- Total Number of Employees
- 721
- Website
- https://www.roivant.com
Valuation
|
Metric
|
ROIV
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 6.29 |
Price/Sales | 3,439.57 |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
ROIV
|
|---|---|
Quick Ratio | 16.27 |
Current Ratio | 16.72 |
Interest Coverage | — |
Quick Ratio
ROIV
Profitability
|
Metric
|
ROIV
|
|---|---|
Return on Assets (Normalized) | −15.59% |
Return on Equity (Normalized) | −18.89% |
Return on Invested Capital (Normalized) | −19.01% |
Return on Assets
ROIV
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|d>%?#w | LOCK|K#xT | $133B | |||
| Moderna Inc
MRNA
| LOCK|>Typyk$ | LOCK|p& | $98B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|tvpx>cs | LOCK|F&jnN | $83B | |||
| argenx SE ADR
ARGX
| LOCK|^JZm#G | LOCK|&W | $56B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|Xz&wg> | LOCK|&?> | $45B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|g#fBJS | LOCK|db!f! | $30B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|b!%f$>< | LOCK|H%<@^ | $28B | |||
| Incyte Corp
INCY
| LOCK|G^>wdpB | LOCK|F^z | $23B | |||
| BioNTech SE ADR
BNTX
| LOCK|!rfh^^r | LOCK|&g | $23B | |||
| Jazz Pharmaceuticals PLC
JAZZ
| LOCK|WNW^yN | LOCK|v# | $14B |
United States